The Cholesterol War Is Over (Here's Who Won)

The speaker argues that the old target of 70 mg/dL is too high and leaves significant benefits on the table. The ESPRIT trial directly compared two targets and proved that aiming for <55 reduces events by a third. The PESA study provides mechanistic backing: plaque begins to form at LDL levels around 50–60 mg/dL, so getting below that threshold is crucial to halt atherosclerosis. The VESALIUS CV diabetic subgroup further supports aggressive lowering in primary prevention. The speaker personally targets <55 and discusses this with patients. He emphasizes that the science is clear: lower is better, earlier is better, and the target most doctors were trained on is probably too high. The frustration is that many clinicians are not adopting this evidence.

The speaker highlights that ezetimibe is generic, costs almost nothing, and is dramatically underused. The ESPRIT study demonstrated that adding ezetimibe to statins can achieve the lower target of <55 mg/dL and reduce cardiovascular events. Despite this, two-thirds of heart disease patients are not at target on statins alone, yet almost nobody prescribes ezetimibe. The speaker personally takes a statin plus ezetimibe and recommends this approach to his patients. He finds the underuse frustrating, calling it a real-world approach that clinicians are ignoring. The combination is a practical, affordable way to implement the new LDL target.

The speaker acknowledges that for patients who cannot reach the <55 mg/dL target with statin plus ezetimibe, PCSK9 inhibitors remain an option. The FOURIER trial showed a 20% reduction in events in secondary prevention, and VESALIUS CV showed 25–31% in primary prevention. However, cost is a major barrier, and insurance companies often reject prescriptions, especially for primary prevention. A new oral PCSK9 inhibitor in phase 3 showed 58% LDL reduction, which could change the landscape by eliminating injections and potentially lowering costs. Until then, injectable PCSK9 inhibitors are effective but underutilized due to access issues.

The speaker argues that waiting until a heart attack or visible atherosclerosis is too late. The PESA data show that even healthy middle-aged adults often have plaque, and the threshold for plaque formation is around 50–60 mg/dL. The VESALIUS CV diabetic subgroup proved that treating before events reduces risk. The concept of 'LDL-years' — cumulative exposure to LDL — drives atherosclerosis. Starting earlier yields greater benefit because it prevents the initiation and slow progression of plaque. The speaker emphasizes that the earlier you start lowering LDL, the more benefit you'll get. This challenges the reactive approach of waiting for disease to declare itself.

The speaker mentions that dietary components like soluble fiber have effectiveness in lowering LDL. He includes psyllium husk, a well-studied source of soluble fiber, in his multivitamin plus powder. He notes that just because he takes a supplement does not mean others should. This is a modest adjunct that can complement medication, but it is not a substitute for pharmacotherapy when aggressive lowering is needed.

Helen Hobbs and Jonathan Cohen, through the Dallas Heart Study, identified individuals with astonishingly low LDL cholesterol. Genetic sequencing revealed loss-of-function mutations in PCSK9 that shut down the protein. The aerobics instructor with LDL of 14 had mutations in both copies of the gene, producing no PCSK9, yet she was perfectly healthy. These carriers had an 88% reduction in coronary heart disease risk. This natural experiment proved that lifelong low LDL is safe and protective. Pharmaceutical companies rapidly developed evolocumab, a monoclonal antibody that neutralizes circulating PCSK9, preserving hepatic LDL receptors. The FOURIER trial in 27,000 patients with existing heart disease showed a 20% reduction in cardiovascular events. The VESALIUS CV trial extended this to primary prevention, showing a 25% reduction in those with atherosclerosis or high-risk diabetes. The latest subgroup analysis in diabetics without atherosclerosis showed a 31% reduction and a signal for 24% lower all-cause mortality. This chain of evidence validates the PCSK9 hypothesis from gene to drug to clinical outcomes, fundamentally changing how we view LDL lowering.

The VESALIUS CV trial included over 12,000 patients with pre-existing atherosclerosis or high-risk diabetes but no prior heart attack or stroke. A pre-specified analysis of just the diabetic subgroup (over 3,000 people) with no significant atherosclerosis and no prior events was presented at ACC 2026. Half received evolocumab, half placebo, followed for 4.8 years. At 48 weeks, LDL in the treatment group dropped to 52 mg/dL vs 110 in placebo; by 98 weeks, median was 44 mg/dL. The primary endpoint (heart attack, stroke, cardiovascular death) occurred in 5% vs 7.1% — a 31% relative risk reduction (HR 0.69). Exploratory analysis showed a 24% lower risk of all-cause mortality (HR 0.76). Benefit emerged after the first year, consistent with slow plaque prevention. Dr. Nicholas Masston stated, 'I think the study changes the paradigm. We don't have to wait until someone has atherosclerosis to treat them intensively.' This suggests that even in diabetes without visible disease, aggressive LDL lowering prevents first events, and waiting costs lives.

The ESPRIT study enrolled 3,048 patients with established cardiovascular disease across 17 centers in South Korea, randomized to intensive (target <55) vs standard (<70). Achieved median LDL: 56 vs 66 mg/dL. The primary outcome (cardiovascular death, MI, stroke, revascularization, unstable angina) occurred in 6.6% vs 9.7% — a 33% relative risk reduction (HR 0.67). Non-fatal MI was more than halved (HR 0.46), and any revascularization had HR 0.63. There were no safety signals. Dr. Christopher Cannon commented, '55 is our new goal.' The study used ezetimibe as add-on to statins, demonstrating that a cheap generic can achieve this lower target. Only 60.8% reached <55, yet the benefit was clear. This aligns with PESA data showing plaque threshold around 50–60 mg/dL. The speaker personally aims for this target and discusses it with patients.

The PESA study used advanced imaging to detect atherosclerosis in apparently healthy middle-aged adults with no cardiovascular disease. In a subgroup with no conventional risk factors (normal blood pressure, no obesity, no insulin resistance), 49% already had plaque. The relationship between LDL cholesterol and plaque burden was linear: plaque was present even at LDL of 60 mg/dL, and prevalence climbed to 64% at LDL 150–160. The authors concluded that plaque buildup appears to only develop at an LDL threshold of approximately 50–60 mg/dL — the very range now targeted by new guidelines. This data underpins the speaker's personal target and his free health roadmap tool. It suggests that waiting for LDL to rise above traditional cutoffs allows silent atherosclerosis to progress.

The ESPRIT study used ezetimibe to get patients from 66 to 56 mg/dL. Despite its proven benefit, only 6% of patients with established cardiovascular disease are on it. Cardiologist Karen Aspry called the ESPRIT study 'a real-world approach for how clinicians should be titrating to a lower target using ezetimibe, which many are not doing.' Two-thirds of heart disease patients aren't at LDL target on statins alone. The speaker finds this frustrating: a cheap, off-patent pill that could help most patients reach the new goal is almost never prescribed. He personally takes a statin plus ezetimibe and discusses the 55 target with his patients. This underuse represents a major public health failure.

For patients who cannot reach target with statin plus ezetimibe, PCSK9 inhibitors remain an option, but cost and insurance rejections are major barriers. The speaker notes that a new oral PCSK9 inhibitor recently demonstrated a 58% LDL reduction in a phase 3 trial. When approved, it could eliminate the need for injections and potentially lower costs, making aggressive LDL lowering feasible for a much broader population. This would address the current inequity where only those who can afford or get approval for injectables can achieve ultra-low LDL.